MORRISVILLE, N.C., January 20, 2022 – A recent study expanded on the value of MyoStress® during needle-free stress testing inpatients with coronary artery disease (CAD), using another non-pharmacologic stress method: dynamic handgrip exercise (DHE).
DHE may have the potential to address the shortcomings of pharmacological stress tests, especially those that require the injection of contrast material to help the reader identify visual defects. Some patients have stress agent and contrast-related reactions or allergies, complicating traditional stress testing techniques.
Two minutes of DHE at 80contractions per minute caused inotropic and chronotropic effects, superior to pharmacological stimulation using intermediate doses of dobutamine. Compared with conventional pharmacological stress testing using dobutamine, a DHE with MyoStress saved significant time (19 minutes, 36 seconds versus 2 minutes, 20 seconds).
MyoStress offers quick and reproducible options for needle-free detection of obstructive CAD. Consistent with previously published results, MyoStress demonstrated excellent reproducibility, detecting stress-induced functional impairment from CAD.
“Much like the use of breathing maneuvers to stress the heart, DHE provides another option for physicians and patients to avoid the use of contrast and pharmacological agents during stress testing.” said Dr. Luis Suarez, Director Medical Affairs, Myocardial Solutions. “Providing needle-free and radiation-free alternatives to existing stress testing modalities mitigates traditional stress testing risks while improving speed and ease."
Access to the publication is available here.
 Ochs A, Nippes M, Salatzki J, Weberling LD, Riffel J, Müller-Hennessen M, Giannitsis E, Osman N, Stehning C, André F, Katus HA, Frey N, Friedrich MG and Ochs MM (2021) Dynamic Handgrip Exercise: Feasibility and Physiologic Stress Response of a Potential Needle-Free Cardiac Magnetic Resonance Stress Test. Front. Cardiovasc. Med. 8:755759. https://doi.org/10.3389/fcvm.2021.755759
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 500 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.